Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics
Delveinsight
JANUARY 7, 2021
The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. The startup recently raised USD 87 million to propel itself in a competitive market. Ikena will back a pipeline that falls into two categories.
Let's personalize your content